Management of Uncomplicated Luminal Crohn's Disease.
出版信息
Gastroenterol Hepatol (N Y). 2025 Mar;21(1 Suppl 1):2-4.
Abstract
摘要
相似文献
1
Management of Uncomplicated Luminal Crohn's Disease.
Gastroenterol Hepatol (N Y). 2025 Mar;21(1 Suppl 1):2-4.
2
Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
Aliment Pharmacol Ther. 2005 Oct 1;22(7):613-26. doi: 10.1111/j.1365-2036.2005.02635.x.
3
Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease.
Gut. 2002 Mar;50(3):307-13. doi: 10.1136/gut.50.3.307.
4
Crohn's disease in endoscopic remission, obesity, and cases of high genetic risk demonstrates overlapping shifts in the colonic mucosal-luminal interface microbiome.
Genome Med. 2022 Aug 15;14(1):91. doi: 10.1186/s13073-022-01099-7.
5
Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies.
Aliment Pharmacol Ther. 2007 Mar 1;25(5):557-67. doi: 10.1111/j.1365-2036.2006.03239.x.
6
Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Aliment Pharmacol Ther. 2005 Dec;22(11-12):1107-13. doi: 10.1111/j.1365-2036.2005.02670.x.
7
[Anti-TNF therapy in treatment of luminal Crohn's disease].
Acta Med Croatica. 2013 Apr;67(2):179-89.
8
Clinical trials in luminal Crohn's disease: a historical perspective.
J Crohns Colitis. 2014 Nov;8(11):1339-50. doi: 10.1016/j.crohns.2014.04.007. Epub 2014 May 17.
9
Advancing therapeutic frontiers: a pipeline of novel drugs for luminal and perianal Crohn's disease management.
Therap Adv Gastroenterol. 2024 Dec 19;17:17562848241303651. doi: 10.1177/17562848241303651. eCollection 2024.
10
Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis.
Gut. 2011 Mar;60(3):325-33. doi: 10.1136/gut.2010.216929. Epub 2010 Nov 12.
本文引用的文献
1
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585.
2
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY).
Gastroenterology. 2024 Oct;167(5):919-933. doi: 10.1053/j.gastro.2024.05.006. Epub 2024 May 23.
3
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
Lancet Gastroenterol Hepatol. 2024 May;9(5):415-427. doi: 10.1016/S2468-1253(24)00034-7. Epub 2024 Feb 22.
4
Evidence-Based Approach to the Management of Mild Crohn's Disease.
Clin Gastroenterol Hepatol. 2024 Mar;22(3):480-483. doi: 10.1016/j.cgh.2023.11.011. Epub 2023 Dec 20.
5
Early Ileocecal Resection for Crohn's Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study.
Gastroenterology. 2023 Oct;165(4):976-985.e3. doi: 10.1053/j.gastro.2023.05.051. Epub 2023 Jun 13.
6
Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.
N Engl J Med. 2023 May 25;388(21):1966-1980. doi: 10.1056/NEJMoa2212728.
7
5-aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn's disease-A nationwide cohort study.
Aliment Pharmacol Ther. 2023 May;57(9):1004-1013. doi: 10.1111/apt.17419. Epub 2023 Mar 9.
8
Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Clin Gastroenterol Hepatol. 2023 Apr;21(4):907-921.e2. doi: 10.1016/j.cgh.2022.07.032. Epub 2022 Aug 6.
Zotero 插件